tiprankstipranks
Summit Therapeutics (SMMT)
NASDAQ:SMMT
US Market
SMMT
Summit Therapeutics
RESEARCH TOOLSreports
Want to see SMMT full AI Analyst Report?

Summit Therapeutics (SMMT) Stock Forecast & Price Target

1,971 Followers
See the Price Targets and Ratings of:

SMMT Analyst Ratings

Moderate Buy
14Ratings
Moderate Buy
8 Buy
6 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Summit
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SMMT Stock 12 Month Forecast

Average Price Target

$28.35
▲(99.26% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Summit Therapeutics in the last 3 months. The average price target is $28.35 with a high forecast of $41.00 and a low forecast of $11.90. The average price target represents a 99.26% change from the last price of $14.23.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","18":"$18","26":"$26","34":"$34","42":"$42"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$41.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.354545454545452,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.90</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,18,26,34,42],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.16,16.224615384615383,18.28923076923077,20.353846153846156,22.41846153846154,24.483076923076922,26.54769230769231,28.612307692307695,30.676923076923078,32.74153846153847,34.80615384615385,36.87076923076923,38.93538461538462,{"y":41,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.16,15.251888111888112,16.343776223776224,17.435664335664335,18.527552447552445,19.61944055944056,20.71132867132867,21.803216783216783,22.895104895104893,23.986993006993004,25.078881118881117,26.170769230769228,27.26265734265734,{"y":28.354545454545452,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.16,13.986153846153845,13.812307692307693,13.638461538461538,13.464615384615385,13.29076923076923,13.116923076923078,12.943076923076923,12.76923076923077,12.595384615384615,12.421538461538463,12.247692307692308,12.073846153846155,{"y":11.9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.49,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.49,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.06,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.19,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.92,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.115,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.71,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.38,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.02,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.16,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$41.00Average Price Target$28.35Lowest Price Target$11.90
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on SMMT
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Reiterated
09/03/26
Analysts Offer Insights on Healthcare Companies: Newron Pharmaceuticals SpA (Other OTC: NWPHF) and Summit Therapeutics (NASDAQ: SMMT)
Mizuho Securities Analyst forecast on SMMT
Mara Goldstein
Mizuho Securities
Mizuho Securities
$31
Buy
117.85%
Upside
Reiterated
09/03/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Citi Analyst forecast on SMMT
Yigal Nochomovitz
Citi
Citi
$40
Buy
181.10%
Upside
Reiterated
09/02/26
Summit Therapeutics: Ivonescimab’s Strengthened Survival Data Supports Buy Rating and Maintained $40 Price Target
Goldman Sachs Analyst forecast on SMMT
Salveen Richter
Goldman Sachs
Goldman Sachs
$41
Buy
188.12%
Upside
Reiterated
09/02/26
Analysts Are Bullish on Top Healthcare Stocks: Summit Therapeutics (SMMT), Definitive Healthcare Corp (DH)
Wells Fargo Analyst forecast on SMMT
Mohit Bansal
Wells Fargo
Wells Fargo
$30
Buy
110.82%
Upside
Reiterated
08/26/26
Analysts' Top Healthcare Picks: Cytokinetics (CYTK), Summit Therapeutics (SMMT)
Bernstein Analyst forecast on SMMT
Jeffrey Walch
Bernstein
Bernstein
$9.8→$11.9
Hold
-16.37%
Downside
Upgraded
08/25/26
Summit Therapeutics upgraded to Market Perform from Underperform at BernsteinSummit Therapeutics upgraded to Market Perform from Underperform at Bernstein
UBS Analyst forecast on SMMT
David Dai
UBS
UBS
$33
Buy
131.90%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (NASDAQ: TNGX), Rein Therapeutics (NASDAQ: RNTX) and Summit Therapeutics (NASDAQ: SMMT)
Wolfe Research Analyst forecast on SMMT
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Reiterated
08/16/26
Balanced Risk-Reward on Summit Therapeutics as Ivonescimab Lung Cancer Data Show Weaker PFS but Encouraging Overall Survival, Supporting Hold Rating
Barclays Analyst forecast on SMMT
Etzer Darout
Barclays
Barclays
$18
Hold
26.49%
Upside
Reiterated
08/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (NASDAQ: STRO), Summit Therapeutics (NASDAQ: SMMT) and Altimmune (NASDAQ: ALT)
Stifel Nicolaus Analyst forecast on SMMT
Dara Azar
Stifel Nicolaus
Stifel Nicolaus
$38
Buy
167.04%
Upside
Reiterated
07/28/26
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Argenx Se (NASDAQ: ARGX)
TD Cowen Analyst forecast on SMMT
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
07/27/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Gossamer Bio (NASDAQ: GOSS)
Jefferies Analyst forecast on SMMT
Faisal Khurshid
Jefferies
Jefferies
$17→$15
Hold
5.41%
Upside
Reiterated
07/24/26
Summit Therapeutics price target lowered to $15 from $17 at JefferiesSummit Therapeutics price target lowered to $15 from $17 at Jefferies
Piper Sandler Analyst forecast on SMMT
Kelsey Goodwin
Piper Sandler
Piper Sandler
$16
Hold
12.44%
Upside
Reiterated
07/24/26
Piper Sandler Keeps Their Hold Rating on Summit Therapeutics (SMMT)
Guggenheim Analyst forecast on SMMT
Bradley Canino
Guggenheim
Guggenheim
$40→$38
Buy
167.04%
Upside
Assigned
07/23/26
Summit Therapeutics price target lowered to $38 from $40 at GuggenheimSummit Therapeutics price target lowered to $38 from $40 at Guggenheim
Evercore ISI Analyst forecast on SMMT
Cory Kasimov
Evercore ISI
Evercore ISI
$34
Buy
138.93%
Upside
Reiterated
05/01/26
Evercore ISI Sticks to Their Buy Rating for Summit Therapeutics (SMMT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on SMMT
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Reiterated
09/03/26
Analysts Offer Insights on Healthcare Companies: Newron Pharmaceuticals SpA (Other OTC: NWPHF) and Summit Therapeutics (NASDAQ: SMMT)
Mizuho Securities Analyst forecast on SMMT
Mara Goldstein
Mizuho Securities
Mizuho Securities
$31
Buy
117.85%
Upside
Reiterated
09/03/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Citi Analyst forecast on SMMT
Yigal Nochomovitz
Citi
Citi
$40
Buy
181.10%
Upside
Reiterated
09/02/26
Summit Therapeutics: Ivonescimab’s Strengthened Survival Data Supports Buy Rating and Maintained $40 Price Target
Goldman Sachs Analyst forecast on SMMT
Salveen Richter
Goldman Sachs
Goldman Sachs
$41
Buy
188.12%
Upside
Reiterated
09/02/26
Analysts Are Bullish on Top Healthcare Stocks: Summit Therapeutics (SMMT), Definitive Healthcare Corp (DH)
Wells Fargo Analyst forecast on SMMT
Mohit Bansal
Wells Fargo
Wells Fargo
$30
Buy
110.82%
Upside
Reiterated
08/26/26
Analysts' Top Healthcare Picks: Cytokinetics (CYTK), Summit Therapeutics (SMMT)
Bernstein Analyst forecast on SMMT
Jeffrey Walch
Bernstein
Bernstein
$9.8→$11.9
Hold
-16.37%
Downside
Upgraded
08/25/26
Summit Therapeutics upgraded to Market Perform from Underperform at BernsteinSummit Therapeutics upgraded to Market Perform from Underperform at Bernstein
UBS Analyst forecast on SMMT
David Dai
UBS
UBS
$33
Buy
131.90%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (NASDAQ: TNGX), Rein Therapeutics (NASDAQ: RNTX) and Summit Therapeutics (NASDAQ: SMMT)
Wolfe Research Analyst forecast on SMMT
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Reiterated
08/16/26
Balanced Risk-Reward on Summit Therapeutics as Ivonescimab Lung Cancer Data Show Weaker PFS but Encouraging Overall Survival, Supporting Hold Rating
Barclays Analyst forecast on SMMT
Etzer Darout
Barclays
Barclays
$18
Hold
26.49%
Upside
Reiterated
08/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (NASDAQ: STRO), Summit Therapeutics (NASDAQ: SMMT) and Altimmune (NASDAQ: ALT)
Stifel Nicolaus Analyst forecast on SMMT
Dara Azar
Stifel Nicolaus
Stifel Nicolaus
$38
Buy
167.04%
Upside
Reiterated
07/28/26
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Argenx Se (NASDAQ: ARGX)
TD Cowen Analyst forecast on SMMT
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
07/27/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Gossamer Bio (NASDAQ: GOSS)
Jefferies Analyst forecast on SMMT
Faisal Khurshid
Jefferies
Jefferies
$17→$15
Hold
5.41%
Upside
Reiterated
07/24/26
Summit Therapeutics price target lowered to $15 from $17 at JefferiesSummit Therapeutics price target lowered to $15 from $17 at Jefferies
Piper Sandler Analyst forecast on SMMT
Kelsey Goodwin
Piper Sandler
Piper Sandler
$16
Hold
12.44%
Upside
Reiterated
07/24/26
Piper Sandler Keeps Their Hold Rating on Summit Therapeutics (SMMT)
Guggenheim Analyst forecast on SMMT
Bradley Canino
Guggenheim
Guggenheim
$40→$38
Buy
167.04%
Upside
Assigned
07/23/26
Summit Therapeutics price target lowered to $38 from $40 at GuggenheimSummit Therapeutics price target lowered to $38 from $40 at Guggenheim
Evercore ISI Analyst forecast on SMMT
Cory Kasimov
Evercore ISI
Evercore ISI
$34
Buy
138.93%
Upside
Reiterated
05/01/26
Evercore ISI Sticks to Their Buy Rating for Summit Therapeutics (SMMT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
BLTEBelite Bio, Inc. ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Summit Therapeutics

3 Months
Asthika GoonewardeneTruist Financial
Success Rate
6/11 ratings generated profit
55%
Average Return
+0.95%
Copying Asthika Goonewardene's trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +0.95% per trade.
1 Year
Bradley CaninoGuggenheim
Success Rate
5/11 ratings generated profit
45%
Average Return
+140.17%
Copying Bradley Canino's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +140.17% per trade.
2 Years
Bradley CaninoGuggenheim
Success Rate
4/11 ratings generated profit
36%
Average Return
+88.37%
Copying Bradley Canino's trades and holding each position for 2 Years would result in 36.36% of your transactions generating a profit, with an average return of +88.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SMMT Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
15
16
18
15
15
Buy
5
5
4
1
1
Hold
7
7
12
15
14
Sell
0
1
1
2
1
Strong Sell
2
2
2
0
0
total
29
31
37
33
31
In the current month, SMMT has received 16 Buy Ratings, 14 Hold Ratings, and 1 Sell Ratings. SMMT average Analyst price target in the past 3 months is 28.35.
Each month's total comprises the sum of three months' worth of ratings.

SMMT Financial Forecast

SMMT Earnings Forecast

Next quarter’s earnings estimate for SMMT is -$0.29 with a range of -$0.42 to -$0.18. The previous quarter’s EPS was -$0.28. SMMT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year SMMT has Performed in-line its overall industry.
Next quarter’s earnings estimate for SMMT is -$0.29 with a range of -$0.42 to -$0.18. The previous quarter’s EPS was -$0.28. SMMT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year SMMT has Performed in-line its overall industry.

SMMT Sales Forecast

Next quarter’s sales forecast for SMMT is $71.00K with a range of $0.00 to $500.00K. The previous quarter’s sales results were $0.00. SMMT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year SMMT has Performed in-line its overall industry.
Next quarter’s sales forecast for SMMT is $71.00K with a range of $0.00 to $500.00K. The previous quarter’s sales results were $0.00. SMMT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year SMMT has Performed in-line its overall industry.

SMMT Stock Forecast FAQ

What is SMMT’s average 12-month price target, according to analysts?
Based on analyst ratings, Summit Therapeutics’s 12-month average price target is 28.35.
    What is SMMT’s upside potential, based on the analysts’ average price target?
    Summit Therapeutics has 99.26% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SMMT a Buy, Sell or Hold?
          Summit Therapeutics has a consensus rating of Moderate Buy which is based on 8 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Summit Therapeutics’s price target?
            The average price target for Summit Therapeutics is 28.35. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $41.00 ,the lowest forecast is $11.90. The average price target represents 99.26% Increase from the current price of $14.23.
              What do analysts say about Summit Therapeutics?
              Summit Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of SMMT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.